MacroGenics Announces Pricing of Public Offering of Common

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
30
MacroGenics Announces Pricing of Public Offering of Common Stock

ROCKVILLE, MD, Feb. 12, 2019 (GLOBE NEWSWIRE) --  

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions. In addition, MacroGenics has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

SVB Leerink, Evercore ISI, Credit Suisse and Stifel are acting as joint book-running managers of the proposed offering. Nomura, SunTrust Robinson Humphrey and BTIG are acting as lead managers and H.C. Wainwright & Co. is acting as co-manager. The offering is expected to close on or about February 15, 2019, subject to customary closing conditions.

MacroGenics anticipates the total gross proceeds from the offering (before deducting underwriters’ discounts and commissions and estimated offering expenses) will be approximately $110 million, excluding any exercise of the underwriters’ option to purchase additional shares. MacroGenics intends to use the proceeds of this offering, together with its existing cash, cash equivalents and marketable securities, for general corporate purposes and working capital needs consistent with MacroGenics’ business plan which would include, but would not be limited to: (i) potential funding of activities in preparation for the potential regulatory approval and marketing of margetuximab in the U.S.; (ii) potential late-stage development of enoblituzumab for the treatment of B7-H3 positive cancers, potentially including squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others; (iii) potential development of margetuximab in combination with MGA012 for the treatment of gastric cancer; (iv) continued development of immune checkpoint-based DART® product candidates; (v) further investment in the development of current pipeline programs as they continue to mature; (vi) other research and development programs; and (vii) in-licensing or acquiring other products or technologies.

The shares are being offered by MacroGenics pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC). A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting one of the following: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800-808-7525, ext. 6132 or by email at syndicate@svbleerink.com; or from Evercore Group L.L.C. at Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about prospective financings, future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, market and other financing conditions, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.

CONTACT: Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, info@macrogenics.com Karen Sharma, Vice President MacDougall Biomedical Communications 1-781-235-3060, ksharma@macbiocom.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 0

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 55

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 275

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 71

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 218

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 178

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

Balavant Insurance Group Welcomes John Jankowski as CIO

Updated Category News Views 317

Leadership Appointment at Balavant Insurance Group Balavant Insurance Group has made a significant move by appointing John Jankowski as its new Chief Information Officer. This announcement marks a pivotal moment for the company, known for its focus on technological advancement and innovative insurance solutions. Strategic Role of the Chief Information Officer In his role,...

Continue Reading
Exploring the Growth of the Industrial Absorbent Sector

Updated Category News Views 245

Understanding the Industrial Absorbent Market Dynamics The industrial absorbent market is poised for remarkable growth, expected to reach $5.50 billion by 2031. This growth trajectory aligns with a compound annual growth rate (CAGR) of 4.3%. The increase in market size is largely driven by the rising usage of absorbents across various industries in response to...

Continue Reading
ChoiceOne Financial Services Achieves Successful Bank Merger

Updated Category News Views 147

Successful Bank Merger by ChoiceOne Financial Services ChoiceOne Financial Services, Inc. (NASDAQ: COFS), the parent company of ChoiceOne Bank, has achieved a significant milestone by completing the consolidation of The State Bank into ChoiceOne Bank. This strategic move empowers the strength of ChoiceOne, further enhancing its service capabilities and market presence. A...

Continue Reading
Danantara Indonesia and INA Forge Nickel Investment Alliance with Eramet

Updated Category News Views 443

Strategic Collaboration for Nickel Development In a significant move to bolster the nickel downstream industry, partners including Danantara Indonesia and the Indonesia Investment Authority (INA) have officially signed a Memorandum of Understanding (MoU) with the prominent French mining company, Eramet. This collaboration aims to create an extensive investment platform...

Continue Reading
Full Moon Bar-B-Que's Generous Initiative for Local Kids

Updated Category News Views 180

Full Moon Bar-B-Que's Generosity In a heartwarming gesture, Full Moon Bar-B-Que has made a significant impact on the community by contributing $200,000 worth of backpacks and school supplies. Their ongoing commitment through the Backpack Blessings program is not just about donations; it's about nurturing and empowering local children who need support the most. Supporting...

Continue Reading